Literature DB >> 18083379

Angiogenesis in melanoma.

Ganapati H Mahabeleshwar1, Tatiana V Byzova.   

Abstract

The process of angiogenesis is crucial for progression and metastasis of the majority of solid tumors including melanomas. The current review summarizes existing knowledge of the mechanisms of angiogenesis in melanoma, as well as current anti-angiogenic therapeutic strategies and their targets. We focus primarily on the role of key growth factors that are secreted by melanoma cells and known to trigger angiogenic responses, and their receptors as expressed on both endothelial and melanoma cells. Many of these growth factors function in synergy with receptors for extracellular matrix, integrins, and matrix metalloproteinases (MMPs). All of these systems of molecules are activated during major stages of angiogenesis such as endothelial migration, proliferation, and reorganization of surrounding extracellular matrix. The blockade of these molecules and their downstream pathways leads to inhibition of melanoma vascularization. Thus, these classes of molecules are essential for melanoma angiogenesis and, therefore, might serve as promising targets for therapeutic intervention. Many recently developed compounds targeting key pathways in angiogenesis are in their final stages of clinical trials.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18083379      PMCID: PMC2365306          DOI: 10.1053/j.seminoncol.2007.09.009

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  85 in total

Review 1.  Structure and function of matrix metalloproteinases and TIMPs.

Authors:  Hideaki Nagase; Robert Visse; Gillian Murphy
Journal:  Cardiovasc Res       Date:  2006-01-05       Impact factor: 10.787

Review 2.  The placenta growth factor in skin angiogenesis.

Authors:  Teresa Odorisio; Francesca Cianfarani; Cristina Maria Failla; Giovanna Zambruno
Journal:  J Dermatol Sci       Date:  2005-10-10       Impact factor: 4.563

Review 3.  Integrins: molecular targets in cancer therapy.

Authors:  Gordon C Tucker
Journal:  Curr Oncol Rep       Date:  2006-03       Impact factor: 5.075

4.  Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins alphavbeta3 and alphavbeta5 in patients with advanced solid tumours.

Authors:  F A L M Eskens; H Dumez; R Hoekstra; A Perschl; C Brindley; S Böttcher; W Wynendaele; J Drevs; J Verweij; A T van Oosterom
Journal:  Eur J Cancer       Date:  2003-05       Impact factor: 9.162

5.  Phase I clinical and pharmacological evaluation of the multi-tyrosine kinase inhibitor SU006668 by chronic oral dosing.

Authors:  Cristiana Sessa; Lucia Viganò; Giacomo Grasselli; Josè Trigo; Irene Marimon; Anna Lladò; Alberta Locatelli; Nicoletta Ielmini; Silvia Marsoni; Luca Gianni
Journal:  Eur J Cancer       Date:  2006-01-06       Impact factor: 9.162

Review 6.  Lessons from phase III clinical trials on anti-VEGF therapy for cancer.

Authors:  Rakesh K Jain; Dan G Duda; Jeffrey W Clark; Jay S Loeffler
Journal:  Nat Clin Pract Oncol       Date:  2006-01

Review 7.  Angiogenesis.

Authors:  Judah Folkman
Journal:  Annu Rev Med       Date:  2006       Impact factor: 13.739

Review 8.  Ultraviolet radiation and cutaneous malignant melanoma.

Authors:  Chamelli Jhappan; Frances P Noonan; Glenn Merlino
Journal:  Oncogene       Date:  2003-05-19       Impact factor: 9.867

Review 9.  Matrix metalloproteinase inhibitors (MMPIs): the beginning of phase I or the termination of phase III clinical trials.

Authors:  Maria Pavlaki; Stanley Zucker
Journal:  Cancer Metastasis Rev       Date:  2003 Jun-Sep       Impact factor: 9.264

Review 10.  Antiangiogenic cancer therapies get their act together: current developments and future prospects of growth factor- and growth factor receptor-targeted approaches.

Authors:  Jens Gille
Journal:  Exp Dermatol       Date:  2006-03       Impact factor: 3.960

View more
  52 in total

1.  A vaccine targeting basic fibroblast growth factor elicits a protective immune response against murine melanoma.

Authors:  Xiaoping Zhang; Neng-Lian Li; Chao Guo; Ying-Dong Li; Lu-Lu Luo; Yong-Qi Liu; Yun-Yan Duan; Zhen-Dong Li; Xiao-Rong Xie; Hai-Xia Song; Li-Ping Yang; Fang-Yu An
Journal:  Cancer Biol Ther       Date:  2018-03-06       Impact factor: 4.742

Review 2.  Dormancy of metastatic melanoma.

Authors:  Liliana Ossowski; Julio A Aguirre-Ghiso
Journal:  Pigment Cell Melanoma Res       Date:  2009-10-19       Impact factor: 4.693

3.  S100A13 is a new angiogenic marker in human melanoma.

Authors:  Daniela Massi; Matteo Landriscina; Annamaria Piscazzi; Elena Cosci; Alek Kirov; Milena Paglierani; Claudia Di Serio; Vasileios Mourmouras; Stefano Fumagalli; Maurizio Biagioli; Igor Prudovsky; Clelia Miracco; Marco Santucci; Niccolò Marchionni; Francesca Tarantini
Journal:  Mod Pathol       Date:  2010-03-05       Impact factor: 7.842

4.  Label-free oxygen-metabolic photoacoustic microscopy in vivo.

Authors:  Junjie Yao; Konstantin I Maslov; Yu Zhang; Younan Xia; Lihong V Wang
Journal:  J Biomed Opt       Date:  2011-07       Impact factor: 3.170

5.  Targeting angiogenesis in melanoma: prospects for the future.

Authors:  P G Corrie; B Basu; K Ahmad Zaki
Journal:  Ther Adv Med Oncol       Date:  2010-11       Impact factor: 8.168

6.  Aflibercept (VEGF Trap) in inoperable stage III or stage iv melanoma of cutaneous or uveal origin.

Authors:  Ahmad A Tarhini; Paul Frankel; Kim A Margolin; Scott Christensen; Christopher Ruel; Janice Shipe-Spotloe; David R Gandara; Alice Chen; John M Kirkwood
Journal:  Clin Cancer Res       Date:  2011-08-31       Impact factor: 12.531

Review 7.  Isolated limb infusion as a model to test new agents to treat metastatic melanoma.

Authors:  Michael E Lidsky; Paul J Speicher; Betty Jiang; Masahito Tsutsui; Douglas S Tyler
Journal:  J Surg Oncol       Date:  2013-11-20       Impact factor: 3.454

8.  Norepinephrine upregulates VEGF, IL-8, and IL-6 expression in human melanoma tumor cell lines: implications for stress-related enhancement of tumor progression.

Authors:  Eric V Yang; Seung-jae Kim; Elise L Donovan; Min Chen; Amy C Gross; Jeanette I Webster Marketon; Sanford H Barsky; Ronald Glaser
Journal:  Brain Behav Immun       Date:  2008-10-21       Impact factor: 7.217

9.  Paracrine induction of endothelium by tumor exosomes.

Authors:  Joshua L Hood; Hua Pan; Gregory M Lanza; Samuel A Wickline
Journal:  Lab Invest       Date:  2009-09-28       Impact factor: 5.662

10.  Angiogenesis and progression in human melanoma.

Authors:  R Ria; A Reale; A Castrovilli; G Mangialardi; F Dammacco; D Ribatti; A Vacca
Journal:  Dermatol Res Pract       Date:  2010-06-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.